Instil Bio, Inc. Capital Expenditures
Instil Bio, Inc. (TIL) reported Capital Expenditures of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2025-03-04
- Instil Bio, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Instil Bio, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Instil Bio, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $20.66M, a 75.57% decline from fiscal 2022.
- Instil Bio, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $84.59M, a 46.27% increase from fiscal 2021.
- Instil Bio, Inc. payments to acquire property, plant, and equipment for fiscal 2021 was $57.83M, a 13.80% increase from fiscal 2020.
| Period end | Payments to Acquire Property, Plant, and Equipment 1 month | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $0.00 derived: sum of 2 quarters · filed 2025-03-04 | $0.00 derived: sum of 3 quarters · filed 2025-03-04 | $0.00 10-K · filed 2025-03-04 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $58.00K derived: sum of 4 quarters · filed 2025-03-04 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $58.00K derived: sum of 3 quarters · filed 2025-03-04 | $5.22M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-10 | $58.00K derived: sum of 2 quarters · filed 2025-03-04 | $5.22M derived: sum of 3 quarters · filed 2025-03-04 | $12.20M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $5.22M derived: sum of 2 quarters · filed 2025-03-04 | $12.20M derived: sum of 3 quarters · filed 2025-03-04 | $20.66M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $5.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $12.14M derived: sum of 2 quarters · filed 2024-11-13 | $20.61M 10-Q · filed 2024-11-13 | $33.62M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $6.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $15.45M 10-Q · filed 2024-08-13 | $28.46M derived: sum of 3 quarters · filed 2024-08-13 | $53.66M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $8.47M 10-Q · filed 2024-05-10 | $21.48M derived: sum of 2 quarters · filed 2024-05-10 | $46.68M derived: sum of 3 quarters · filed 2024-05-10 | $72.82M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | $13.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $38.21M derived: sum of 2 quarters · filed 2024-03-21 | $64.35M derived: sum of 3 quarters · filed 2024-03-21 | $84.59M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $25.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $51.34M derived: sum of 2 quarters · filed 2023-11-13 | $71.58M 10-Q · filed 2023-11-13 | $90.04M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $26.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $46.38M 10-Q · filed 2023-08-14 | $64.84M derived: sum of 3 quarters · filed 2023-08-14 | $86.59M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $20.23M 10-Q · filed 2023-05-11 | $38.70M derived: sum of 2 quarters · filed 2023-05-11 | $60.44M derived: sum of 3 quarters · filed 2023-05-11 | $68.94M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $18.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $40.21M derived: sum of 2 quarters · filed 2023-03-31 | $48.70M derived: sum of 3 quarters · filed 2023-03-31 | $57.83M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $21.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $30.24M derived: sum of 2 quarters · filed 2022-11-14 | $39.37M 10-Q · filed 2022-11-14 | $84.64M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $8.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $17.62M 10-Q · filed 2022-08-12 | $62.89M derived: sum of 3 quarters · filed 2022-08-12 | $67.19M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $9.13M 10-Q · filed 2022-05-16 | $54.40M derived: sum of 2 quarters · filed 2022-05-16 | $58.70M derived: sum of 3 quarters · filed 2022-05-16 | $58.98M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | $45.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $49.57M derived: sum of 2 quarters · filed 2022-03-07 | $49.85M derived: sum of 3 quarters · filed 2022-03-07 | $50.82M 10-K · filed 2022-03-07 | |
| 2020-10-31 | $37.60M 10-K · filed 2022-03-07 | ||||
| 2020-09-30 | $4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $4.58M derived: sum of 2 quarters · filed 2021-11-15 | $5.54M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.24M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $968.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |